These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 15848574

  • 1. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M, myPROMS LatAm Study Group.
    Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
    [Abstract] [Full Text] [Related]

  • 2. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

  • 3. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M, Girón F, Hernández E, Juarez F, Liendo C, Novoa P, Toledo M, Myproms Latam Study Group.
    Transplant Proc; 2004 Mar; 36(6):1647-9. PubMed ID: 15350440
    [Abstract] [Full Text] [Related]

  • 4. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B, Suwelack B, Ivens K, Arns W, Lhotta K, Bourbigot B, Budde K, Fischer W, Pietruck F, ERL2405-DE02 Study Group.
    Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
    Budde K, Knoll G, Curtis J, Chan L, Pohanka E, Gentil M, Seifu Y, Marrast AC, Neumayer HH, ERL B302 Study Group.
    Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M.
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G, MYVIDA Study Group.
    Transplantation; 2011 Aug 27; 92(4):426-32. PubMed ID: 21760569
    [Abstract] [Full Text] [Related]

  • 8. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies.
    Pietruck F, Abbud-Filho M, Vathsala A, Massari PU, Po-Huang L, Nashan B.
    Transplant Proc; 2007 Aug 27; 39(1):103-8. PubMed ID: 17275484
    [Abstract] [Full Text] [Related]

  • 9. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
    Feng JJ, Zhang LW, Zhao P, Bow LM, Tian J.
    Int J Clin Pract Suppl; 2015 May 27; (183):1-7. PubMed ID: 26176848
    [Abstract] [Full Text] [Related]

  • 10. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M, Bertoni E, Budde K, Holzer H, Civati G, Lien B, Arns W.
    Transplant Proc; 2010 May 27; 42(4):1325-8. PubMed ID: 20534293
    [Abstract] [Full Text] [Related]

  • 11. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.
    Transplantation; 2007 Feb 27; 83(4):417-24. PubMed ID: 17318074
    [Abstract] [Full Text] [Related]

  • 12. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
    Kobashigawa JA, Renlund DG, Gerosa G, Almenar L, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U, Ross H, Segovia J, Yonan N, ERL2401 Heart Study Investigators.
    J Heart Lung Transplant; 2006 Aug 27; 25(8):935-41. PubMed ID: 16890114
    [Abstract] [Full Text] [Related]

  • 13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study.
    Nashan B, Ivens K, Suwelack B, Arns W, Abbud Filho M, myPROMS DE02 Study Group, LA01 Study Group.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):521S-523S. PubMed ID: 15041400
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
    Budde K, Knoll G, Curtis J, Kahana L, Pohanka E, Seifu Y, Neumayer HH.
    Transplant Proc; 2005 Mar 27; 37(2):912-5. PubMed ID: 15848573
    [Abstract] [Full Text] [Related]

  • 15. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
    Salvadori M, Holzer H, Civati G, Sollinger H, Lien B, Tomlanovich S, Bertoni E, Seifu Y, Marrast AC, ERL B301 Study Group.
    Clin Nephrol; 2006 Aug 27; 66(2):112-9. PubMed ID: 16939067
    [Abstract] [Full Text] [Related]

  • 16. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
    Shehata M, Bhandari S, Venkat-Raman G, Moore R, D'Souza R, Riad H, Bakran A, Baker R, Needham C, Andrews C.
    Transpl Int; 2009 Aug 27; 22(8):821-30. PubMed ID: 19386081
    [Abstract] [Full Text] [Related]

  • 17. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium.
    Calvo N, Sanchez-Fructuoso AI, Conesa J, Moreno A, Barrientos A.
    Transplant Proc; 2006 Oct 27; 38(8):2396-7. PubMed ID: 17097945
    [Abstract] [Full Text] [Related]

  • 18. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.
    Transplant Proc; 2007 Sep 27; 39(7):2194-6. PubMed ID: 17889135
    [Abstract] [Full Text] [Related]

  • 19. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS.
    Transplantation; 2009 Aug 27; 88(4):514-20. PubMed ID: 19696634
    [Abstract] [Full Text] [Related]

  • 20. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
    Burg M, Säemann MD, Wieser C, Kramer S, Fischer W, Lhotta K.
    Transplant Proc; 2009 Dec 27; 41(10):4159-64. PubMed ID: 20005359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.